Vestre Viken HF
- Address
- lock Available on a paid plan
Oncology and Lung Cancer Research
At Vestre Viken HF, the Department of oncology is conducting a large body of research in neoplasms, with a major focus on non-small cell lung cancer and other advanced lung tumors. These studies are designed to test new treatment combinations, improve outcomes after standard therapy, and better define which patients may benefit most from targeted and immune-based approaches.
- Advanced and metastatic non-small cell lung cancer
- EGFR-mutated and KRAS G12C-mutated lung cancer
- HER2-driven breast and lung cancers
- Immunotherapy, targeted therapy, and survival improvement studies
This research includes efforts to refine cancer care through precision medicine, evaluate combinations with pembrolizumab and other modern agents, and support better disease control in difficult-to-treat cancers.
Breast Cancer and Precision Treatment
The site is also active in breast cancer research, especially for HER2-positive and estrogen receptor-positive disease. The trials aim to improve the effectiveness of treatment before surgery, extend disease control in advanced cancer, and compare new targeted strategies with established care.
- HER2-positive and HER2-negative breast cancer
- Triple-negative breast cancer
- Advanced and resected breast cancer
- Testing targeted and immunotherapy-based treatment approaches
Research in this area reflects a strong interest in matching therapy to tumor biology, with the goal of improving response rates and long-term outcomes for patients with breast cancer.
Immune-Mediated and Inflammatory Diseases
Clinical trials at the site cover several immune system diseases and chronic inflammatory conditions, including multiple sclerosis, Crohn's disease, and juvenile idiopathic arthritis. These studies are focused on finding better ways to control disease activity, reduce flares, and improve day-to-day function for patients living with long-term immune-related disorders.
- Multiple sclerosis
- Crohn's disease
- Juvenile idiopathic arthritis
- Evaluating disease control, symptom relief, and treatment durability
The research also includes efforts to compare existing therapies with newer options, helping build clearer evidence for safer and more effective management of chronic inflammatory disease.
Cardiovascular, Metabolic, and Kidney-Related Studies
Another important area of work involves cardiovascular diseases, nutritional and metabolic diseases, and kidney-related complications. Trials here address heart failure, hypertension, obesity, and cardiovascular risk in patients with advanced kidney disease, with the aim of improving prevention and treatment of serious complications.
- Chronic heart failure
- Atherosclerotic cardiovascular disease and type 2 diabetes
- Obesity and cardiovascular safety
- Testing treatment effectiveness and reducing major cardiovascular events
These studies help clarify how newer therapies may lower inflammation, improve heart function, and reduce hospitalizations in patients with complex chronic disease.
Neurology, Stroke, and Vision Research
The research portfolio also includes studies in nervous system diseases and eye diseases. Key topics include amyotrophic lateral sclerosis, acute ischemic stroke, and central retinal artery occlusion, with trials aimed at improving recovery, slowing disease progression, and expanding treatment options in urgent and high-impact conditions.
- Amyotrophic lateral sclerosis
- Acute ischemic stroke
- Central retinal artery occlusion
- Assessing new therapies for neurological protection and visual recovery
This work reflects a broader effort at Vestre Viken HF to advance care in conditions where faster diagnosis and more effective treatment can make a major difference.
Respiratory, Infectious, and Surgical Care Research
The site conducts trials across respiratory tract diseases, virus diseases, and selected analytical, diagnostic and therapeutic techniques. Studies include COVID-19, COPD, and other respiratory infections, as well as research in surgical care aimed at improving recovery and reducing complications.
- COVID-19 and viral respiratory infection
- Chronic obstructive pulmonary disease
- Supportive care and infection management in hospitalized patients
- Improving surgical outcomes and postoperative recovery
Together, these studies are designed to test better treatment strategies, support safer care, and improve outcomes in both acute illness and perioperative settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 16 therapeutic areas and 15 of 148 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 143 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1Oslo University Hospital HF6active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF9trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vestre Viken HF
lock Showing 1 of 49 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years | Helse Bergen HF | Phase III | Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 148 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2020-12-18 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
